HMGA1 Has Predictive Value in Response to Chemotherapy in Gastric Cancer

Diana Pádua 1,2,3, Débora Filipa Pinto 1,2, Paula Figueira 1,2, Carlos Filipe Pereira 4,5,6, Raquel Almeida 1,2,7,8 and Patrícia Mesquita 1,2,*

1 i3S—Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal; dpadua@ipatimup.pt (D.P.); deborafilipapinto@gmail.com (D.F.P.); paulafigueiracp@gmail.com (P.F.); ralmeida@ipatimup.pt (R.A.)
2 IPATIMUP—Institute of Molecular Pathology and Immunology, University of Porto, 4200-465 Porto, Portugal
3 ICBAS—Institute of Biomedical Sciences Abel Salazar, University of Porto, 4050-313 Porto, Portugal
4 CNC—Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal; filipe.pereira@cnc.uc.pt
5 Cell Reprogramming in Hematopoiesis and Immunity Laboratory, Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, BMC A12, 221 84 Lund, Sweden
6 Wallenberg Center for Molecular Medicine, Lund University, 221 84 Lund, Sweden
7 Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
8 Biology Department, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal
* Correspondence: pmesquita@ipatimup.pt

Abstract: Gastric cancer is a serious health problem worldwide. Although its incidence is decreasing, the five-year survival rate remains low. Thus, it is essential to identify new biomarkers that could promote better diagnosis and treatment of patients with gastric cancer. High-mobility group AT-hook 1 (HMGA1) is a non-histone, chromatin-binding protein that has been found overexpressed in several tumor types. It has been correlated with invasion, metastasis, and drug resistance, leading to worse patient survival. The aim of this work was to evaluate the clinical value of HMGA1 in gastric cancer. HMGA1 expression was analyzed by immunohistochemistry in a single hospital series (n = 323) of gastric adenocarcinoma cases (stages I to IV) with clinicopathological and treatment data. In this series, HMGA1 expression showed no significant relevance as a prognostic biomarker. Nevertheless, a significantly better overall survival was observed in cases with high levels of HMGA1 when they were treated with chemotherapy, compared to the nontreated ones, implying that they can benefit more from treatment than patients with low expression of HMGA1. We thereby show for the first time that HMGA1 expression has a substantial value as a biomarker of response to chemotherapy in gastric cancer.

Keywords: HMGA1; gastric cancer; prognosis; predictive value; chemotherapy

1. Introduction

Gastric cancer (GC) remains one of the most commonly diagnosed cancers and the fourth leading cause of global cancer mortality [1]. The majority of GCs are adenocarcinoma (90% to 95%). According to the Laurén classification system, the gastric adenocarcinomas can be histologically classified as intestinal, diffuse and mixed type, depending on tissue architecture and glandular patterns. The diffuse-type involves non-cohesive and poorly differentiated tumors, with no gland formation, while intestinal-type tumors are moderate to differentiated tumors, having glandular structures. The mixed type presents features from both the diffuse and intestinal types [2,3]. GC treatment options depend on the stage of the disease at the time of diagnosis. At the early stages, surgical resection of the tumor is the preferred treatment [4]. For stages IB–III, surgery is recommended along with perioperative or adjuvant chemotherapy in order to improve overall patient survival due to the probable relapse after resection [4]. Yet, a significant number of patients have advanced disease at diagnosis, and, consequently, surgery is no longer an option [5]. Therefore,
for stage IV, first-line chemotherapy with doublet or triplet platinum/fluoropyrimidine combinations or second-line chemotherapy using taxane, ramucirumab or irinotecan alone or in combination with paclitaxel are recommended [4]. Despite all the improvements registered in the diagnosis and treatment of GC in the last decades, patient prognosis remains poor [5,6]. In Europe, five-year survival rates are enormously diverse between different countries, with a maximum value of 37.5% obtained when best practices are used [7]. The heterogeneity of GC at the molecular level plays an important role in terms of tumor aggressiveness, regardless of tumor extension or tumor type [8,9]. This reveals an urgent need to better understand the disease in order to improve diagnostic techniques and treatments. The validation of new biomarkers can allow for a more personalized practice by making it possible to distinguish between patients who may benefit more from systemic treatment at a specific stage of the disease [10,11]. These biomarkers should comprise transcription factors (TFs), as they are essential in the control of regulatory gene networks and cell fate, and their normal activity is usually altered in different types of cancer [11–13].

The transcription factor high-mobility group AT-hook 1 (HMGA1) is a non-histone, chromatin-binding protein with an important role in chromatin remodeling [14]. HMGA1 binds to nuclear chromatin at AT-rich regions located in the minor grooves of DNA, where it bends the chromatin, allowing additional TFs to bind, thereby influencing gene regulation [14,15]. It is involved in DNA repair, cell cycle progression, cell proliferation, cell metabolism, and apoptosis [16–18]. Additionally, HMGA1 prevents embryonic stem cell differentiation by maintaining high levels of OCT4, NANOG, SOX2, and MYC [19]. Consequently, HMGA1 suppression decreased the expression of the pluripotency genes [20]. The HMGA1 protein is also found overexpressed in numerous aggressive human cancers [21–24]. It acts as an oncogene, and its high expression in cancer has been implicated in malignant transformation, tumor progression, and metastasis, while correlated with unfavorable clinical outcomes of the patients [23,25–30]. Accordingly, studies using tumor tissue specimens revealed that high HMGA1 expression is associated with a poor differentiation state and advanced disease or high-grade cancers [31–33]. Although the specific role and molecular mechanisms of HMGA1 in cancer have not been fully uncovered, studies have revealed that HMGA1 overexpression induced cancer cell proliferation, migration/invasion, and contributed to drug resistance in several tumors, including GC [16–18,25,34–41]. In GC, HMGA1 was also shown to stimulate epithelial–mesenchymal transition (EMT), thereby favoring a malignant progression [27]. It was also shown to participate in the regulation of aerobic glycolysis by regulating C-MYC expression [17]. However, the relevance of HMGA1 as a predictive biomarker with potential clinical applications has not been assessed in GC. Thus, the aim of this study was to investigate the clinical value of HMGA1 expression in a robust series of gastric adenocarcinoma cases with clinicopathological and treatment data. The importance of HMGA1 in predicting prognosis and response to therapy in GC patients was assessed by analyzing its expression in 323 cases from a consecutive, single hospital series. We observed that patients having tumors with high expression of HMGA1 benefit significantly more from chemotherapy compared to those with low expression. This observation can irrefutably contribute to a more efficient disease monitoring and treatment planning in GC patients.

2. Materials and Methods

2.1. Patients

Histological materials from 323 GC patients, mean age 67.68 ± 11.85, were collected from surgical specimens of consecutive cases of gastric adenocarcinoma surgically treated between January 2008 and December 2014 at Centro Hospitalar São João (CHSJ), Porto, Portugal. For all patients (n = 323), tumor tissue, clinicopathological and treatment data, as well as follow-up information were available. In addition to surgery, 121 patients out of 323 received platinum- and/or fluoropyrimidine-based chemotherapy, mostly as adjuvant treatments. Relevant clinical information on this series is provided in Mesquita et al. [42] and in the Table S1.
2.2. Tissue Microarrays and Immunohistochemistry

Cores from formalin-fixed, paraffin-embedded tumor tissue blocks from the surgical specimens were used to construct tissue microarrays (TMAs). After construction of the TMAs, they were sectioned with a microtome (Microm HM 335 E) at a thickness of 4 µm, and the expression of HMGA1 was evaluated by immunohistochemistry (IHC) staining using standard protocols described in Mesquita et al. [42]. Rabbit recombinant monoclonal HMGA1 primary antibody (anti-HMGA1, 1:5000 dilution, Abcam ab252930, Cambridge, UK) was incubated overnight at 4 °C in a humidified chamber. Samples were considered HMGA1-low when they were negative for HMGA1 or it was present in less than 20% of the malignant cells and considered HMGA1-high otherwise, in agreement between two observers.

2.3. Statistical Analysis

We aimed to evaluate the association between the expression status of HMGA1 and the clinicopathological features of the tumors, for which we applied different statistical tests. To compare using the patient’s age, we used Student’s t-test. For gender, tumor growth pattern, vascular invasion, perineural invasion, and treatment, we applied Fisher’s exact test (2-sides). For the Laurén classification and tumor node metastasis (TNM) staging, we used the chi-square test ($\chi^2$). We also aimed to investigate the association between HMGA1 expression status and risk of death or relapse. This was done using the Kaplan-Meier method in order to generate plots and survival curves for five-year overall survival (OS—time from operation to death from any cause) and disease-free survival (DFS—time from surgery to the first event of either locoregional recurrence or metastasis or death from the same cancer) that were compared using the log-rank test. To assess whether HMGA1 expression could predict response to chemotherapy, OS and DFS plots were generated according to the expression status of this protein and administration or not of chemotherapy. The Cox proportional hazard model was used to calculate univariate and multivariate hazard ratios and confidence intervals for death. The clinicopathological parameters included in the multivariate models were selected based on their individual clinical relevance. Patients with incomplete data were excluded from the analyses. Statistical analysis of the data was performed using the IBM SPSS Statistics version 24 (IBM Corporation, Armonk, NY, USA). Differences were considered statistically significant when $p$ value < 0.05.

3. Results

3.1. Association of HMGA1 Expression with Clinicopathological Features in Gastric Carcinomas

HMGA1 expression was analyzed by IHC in 323 gastric carcinomas (Figure 1). Expression of HMGA1 was nuclear. High HMGA1 expression was observed in 223 (69%) gastric carcinoma cases (Figure 1A). HMGA1 was absent or low in 100 (31%) cases (Figure 1B). Clinicopathological features of the 323 GC cases and their association with HMGA1 expression are summarized in Table 1.

High levels of HMGA1 were significantly associated with tumors classified as intestinal (in 78% of the cases) or mixed (in 71% of the cases) according to the Laurén classification ($p < 0.001$), in opposition to tumors of the diffuse type (only in 44% of the cases) (Table 1). The other clinicopathological parameters, which included age at diagnosis, gender, growth pattern, TNM, and vascular and perineural invasion were not significantly associated with HMGA1 expression.
Figure 1. Representative immunostaining patterns for HMGA1 protein expression in two different GC cases and the respective percentages in the 323 gastric carcinomas evaluated (20× magnification). (A) GC case with high expression of HMGA1 in the nucleus (brown); 69% of gastric carcinomas express high levels of HMGA1 in the nucleus. (B) GC case with low HMGA1 expression; absence or low levels of HMGA1 were observed in 31% of gastric carcinoma cases. Tissues were counterstained with hematoxylin (purple).

Table 1. Clinicopathological association with HMGA1 expression in 323 patients diagnosed with GC.

|                      | All Cases | HMGA1 High | HMGA1 Low |   |
|----------------------|-----------|------------|-----------|---|
| Patients             | 323       | 223        | 100       | 31.0 |
| Age                  |           |            |           |    |
| Mean ± SD            | 67.68 ± 11.85 | 68.26 ± 11.61 | 66.39 ± 12.32 | 0.19 |
| Range                | 32–95     | 33–95      | 32–87     |    |
| Gender               |           |            |           |    |
| Female               | 140       | 100        | 40        | 28.6 |
| Male                 | 183       | 123        | 60        | 32.8 |
| Laurén Classification|           |            |           |    |
| Intestinal           | 151       | 117        | 34        | 22.5 |
| Diffuse              | 41        | 18         | 23        | 56.1 |
| Mixed                | 85        | 60         | 25        | 29.4 |
| Unclassified         | 46        | 14.2       |           |    |
| Growth Pattern       |           |            |           |    |
| Expansive            | 58        | 38         | 20        | 34.5 |
| Infiltrative         | 252       | 176        | 76        | 30.2 |
| Unclassified         | 13        | 4.0        |           |    |
| TNM                  |           |            |           |    |
| I                    | 106       | 82         | 24        | 22.6 |
| II                   | 86        | 54         | 32        | 37.2 |
| III                  | 68        | 46         | 22        | 32.4 |
| IV                   | 63        | 41         | 22        | 34.9 |
| Vascular Invasion    |           |            |           |    |
| No                   | 134       | 93         | 41        | 30.6 |
| Yes                  | 186       | 128        | 58        | 31.2 |
| ND                   | 3         | 0.9        |           |    |
| Perineural Invasion  |           |            |           |    |
| No                   | 167       | 120        | 47        | 28.1 |
| Yes                  | 156       | 103        | 53        | 34.0 |
| Chemotherapy treatment|          |            |           |    |
| No                   | 200       | 141        | 59        | 29.5 |
| Yes                  | 121       | 80         | 41        | 33.9 |
| ND                   | 2         | 0.6        |           |    |

Notes: \( p \) values (statistical significance threshold < 0.05) were obtained using Student’s \( t \) test for the continuous variable, Fisher’s exact test (2-sided) and Chi-square (\( \chi^2 \)) test for categorical variables; \( * \) comparisons with \( p < 0.05 \). ND = not determined; SD = standard deviation.
3.2. Evaluation of the Prognostic Significance of HMGA1 Expression in GC

To assess the relevance of HMGA1 as a biomarker in our series of 323 patients diagnosed with GC, we started by evaluating if HMGA1 expression predicted patient OS or DFS using the Kaplan-Meier method. HMGA1 showed no significant relevance as a prognostic biomarker (Figure 2A,B) when considering all the patients or when patients were stratified by the TNM stage (Figure 3A–D).

**Figure 2.** Kaplan-Meier curves showing the probability of (A) OS and (B) DFS in our series of patients with GC according to HMGA1 expression. Mean OS is shown for each subgroup of patients. The log-rank test was used to test for differences in survival between cases with high and low expression of HMGA1. *p* value is indicated. The number of patients at risk is specified for 0, 20, 40, and 60 months.

**Figure 3.** Kaplan-Meier curves showing the probability of OS according to HMGA1 expression in different stages of GC: (A) stage I, (B) stage II, (C) stage III, and (D) stage IV. Mean OS is shown for each subgroup of patients. The log-rank test was used to test for differences in survival between cases with high and low expression of HMGA1. *p* value is indicated. The number of patients at risk is specified for 0, 20, 40, and 60 months.
3.3. Evaluation of the Predictive Value of HMGA1 for Response to Chemotherapy in GC

Regarding treatment, 121 (37.5%) patients received chemotherapy, which improved OS \[42\]. The value of HMGA1 as a biomarker of response to chemotherapy was investigated. We observed a significantly better outcome in cases that had high levels of HMGA1 when they were treated with chemotherapy, comparing with those not treated (Figure 4A). The mean OS of patients with HMGA-high tumors treated with chemotherapy was 39 ± 2 months versus 24 ± 3 months in nontreated patients \((p < 0.001)\), and indeed the combination of HMGA1-high expression and no treatment defined the group of patients with the worst outcome regarding OS. We did not observe a significant difference in cases with low levels of HMGA1, with or without chemotherapy (Figure 4B). Accordingly, in the universe of cases treated with chemotherapy, we saw a better outcome for the cases with high expression of HMGA1 (mean OS of 39 ± 2 months) compared to those with low expression (mean OS of 30 ± 3 months), although not significant (Figure 4C; \(p = 0.051\)). In the absence of chemotherapy, we did not observe a significant difference in OS between cases with different levels of HMGA1 expression (Figure 4D). The correlation between HMGA1 expression and adjuvant chemotherapy regarding DFS was also investigated (Figure S1), but we have not observed statistically significant differences.

Figure 4. Kaplan-Meier curves showing the probability of OS according to treatment options in patients having tumors with: (A) high and (B) low expression of HMGA1, respectively. Alternatively, Kaplan-Meier curves showing the probability of OS according to levels of expression of HMGA1 in patients (C) treated or (D) not treated with chemotherapy. Mean OS is shown for each subgroup of patients. The log-rank test was used to test for differences in OS between treatment and absence of treatment (A, B) or between high and low levels of HMGA1 (C, D). \(p\) value is indicated. * comparisons with \(p < 0.05\). The number of patients at risk is specified for 0, 20, 40, and 60 months.
Independently analyzing the cases diagnosed in each TNM stage—II to IV—we observe a clear and significant benefit in treating the tumors diagnosed in stages III and IV that have high expression of HMGA1 ($p < 0.001$ for both stages), whereas the same was not true for those presenting low expression (Figure 5A–F). In stage III, the mean OS for patients having tumors with high levels of HMGA1 was $40 \pm 4$ months in patients treated with adjuvant chemotherapy in addition to surgery, compared to $15 \pm 4$ months in patients not treated. In stage IV, patients having tumors with high levels of HMGA1 that were treated with palliative chemotherapy had a mean OS of $26 \pm 4$ months while those not treated had a mean OS of $6 \pm 2$ months.

Furthermore, HMGA1 expression was independently associated with a lower risk of death in a Cox multivariate analysis restricted to patients diagnosed in stages II–IV treated with chemotherapy and that includes relevant clinicopathological factors such as Laurén classification, growth pattern, TNM staging, and vascular and perineural invasion as covariates (Table 2; HR = 0.53; 95% CI 0.30–0.95; $p = 0.03$).

Table 2. Overall survival univariate and multivariate Cox regression analysis in gastric cancer patients diagnosed in stages II–IV and treated with chemotherapy.

| Number of Events | Univariate Analysis | Multivariate Analysis |
|------------------|---------------------|-----------------------|
|                  | HR                  | 95% CI                | p-Value   | HR          | 95% CI                | p-Value   |
| HMGA1            |                     |                       |           |             |                       |           |
| Low              | 28                  | 1                     |           | 1           | 0.63                  | 0.39–1.01 | 0.06 *               |
| High             | 44                  | 1.51                  | 0.84–2.27 | 0.17        | 1.33                  | 0.61–2.89 | 0.09                  |
| Laurén Classification |               |                       |           |             |                       |           |
| Intestinal       | 23                  | 1                     |           | 1           | 1.75                  | 0.91–3.36 | 0.09                  |
| Diffuse          | 15                  | 1.51                  | 0.84–2.27 | 0.17        | 1.33                  | 0.61–2.89 | 0.09                  |
| Mixed            | 23                  | 1.51                  | 0.84–2.27 | 0.17        | 1.33                  | 0.61–2.89 | 0.09                  |
| Growth pattern   |                     |                       |           |             |                       |           |
| Infiltrative     | 65                  | 1                     |           | 1           | 1.74                  | 0.30–1.83 | 0.51                  |
| Expansive        | 5                   | 1.74                  | 0.30–1.83 | 0.51        | 1.74                  | 0.30–1.83 | 0.51                  |
| TNM              |                     |                       |           |             |                       |           |
| II               | 14                  | 1                     |           | 1           | 2.04                  | 1.07–3.89 | 0.03 *               |
| III              | 27                  | 2.04                  | 1.07–3.89 | 0.03 *      | 2.03                  | 0.96–4.29 | 0.06                  |
| IV               | 32                  | 4.40                  | 2.31–8.38 | <0.001 *    | 4.41                  | 2.08–9.34 | <0.01 *               |
| Vascular Invasion|                     |                       |           |             |                       |           |
| No               | 20                  | 1                     |           | 1           | 1.34                  | 0.80–2.24 | 0.27                  |
| Yes              | 52                  | 1.34                  | 0.80–2.24 | 0.27        | 1.81                  | 0.97–3.38 | 0.06                  |
| Perineural Invasion|                 |                       |           |             |                       |           |
| No               | 20                  | 1                     |           | 1           | 1.65                  | 0.99–2.78 | 0.06                  |
| Yes              | 52                  | 1.65                  | 0.99–2.78 | 0.06        | 1.09                  | 0.58–2.03 | 0.80                  |

Notes: $p$ values (statistical significance threshold $< 0.05$) were obtained using univariate and multivariate Cox proportional hazards regression analysis (Wald); * comparisons with $p < 0.05$. HR = Hazard-ratio; CI = Confidence interval.
Figure 5. Kaplan-Meier curves showing the probability of OS according to treatment options in patients having tumors with: (A,C,E) high and (B,D,F) low expression of HMGA1, in patients diagnosed in: (A,B) stage II, (C,D) stage III, and (E,F) stage IV, respectively. Mean OS is shown for each subgroup of patients. The log-rank test was used to test for differences in survival between treatment and absence of treatment with chemotherapy. $p$ value is indicated. * comparisons with $p < 0.05$. The number of patients at risk is specified for 0, 20, 40, and 60 months.
4. Discussion

In the present study, we determined the value of nuclear HMGA1 expression in predicting GC’s prognosis and response to treatment, in addition to its association with clinicopathological features of the tumors. This assessment was performed using a series of 323 gastric carcinomas, the largest series of tumors used to date for this purpose and the most complete in terms of clinicopathological features, survival data, and treatment data.

We found high levels of nuclear expression of HMGA1 in 69% of the tumors, which is comparable to those observed in all the reports published so far in the series of GC cases: 59% [28], 75% [43], and 74% [30]. An association between high expression of HMGA1 and Laurén intestinal and mixed-type tumors was observed in our series, and this agrees with previous reports of HMGA1 expression in gastric glands [18]. None of the other clinicopathological features were associated with HMGA1 expression. Accordingly, Nam et al. (2003) and Jun et al. (2015) reported no association at all between HMGA1 expression and clinicopathological features evaluated in a series of 62 and 110 GC cases, respectively, despite their analysis not including Laurén mixed-type tumors [30,43]. Contrarily, Yang et al. (2021) observed that increased HMGA1 expression was closely related with differentiation, lymph node metastasis, tumor size, and TNM stage, but this study was performed in a small series with only 51 GC samples [28].

To the best of our knowledge, our study is the first to identify HMGA1 expression as a useful marker to predict response to chemotherapy in GC. Our results unequivocally showed that patients with high levels of HMGA1 expression in the tumor had remarkably better OS rates when undergoing treatment with chemotherapy. This suggests that these patients can benefit more from this type of treatment than patients with low HMGA1 expression, where no significant difference was observed between treated and untreated patients. In the literature, there are several reports in cancer cell lines describing the role of HMGA1 expression in conferring resistance to antineoplastic drugs [44–46], including in GC [41]. These observations are in apparent contradiction with our results, if we consider only the association of HMGA1 with chemoresistance [47]. However, when we consider that HMGA1-high expression has been associated with features of higher malignancy in GC, such as increased proliferation, migration, metastasis, and EMT [18,27,28], the observation that HMGA1-tumors have better outcomes when subjected to more aggressive treatments is not surprising. Our results suggest that this parameter should be considered to determine which patients may benefit more from intensive chemotherapy management in an attempt to perform a more personalized medicine. This conclusion has a great impact because it advises for the treatment with chemotherapy of the 65% of GC patients with high HMGA1 expression diagnosed in stages II–IV. Considering only the cases with high expression of HMGA1 detected in stages III and IV, where the significant and most striking differences were obtained in mean OS values, our data supports the selection of 40% of the GC patients diagnosed in all tumor stages, except stage I, for treatment. Besides this role we describe for HMGA1 in predicting chemotherapy response, the role described for HMGA1 as a glycolysis regulator in gastric cancer suggests that the HMGA1-c-Myc-glycolysis axis may also be used as a new target in cancer therapy in combination with commonly used chemotherapeutic agents [17].

High expression of HMGA1 has already been correlated with worse survival in GC patients but only in studies that used series with a relatively small number of cases [28,43] or TCGA/GEPIA datasets [17,27]. High expression of another member of the family, HMGA2, has also been reported as predicting bad prognoses in two series of Asian GC patients [43,48]. However, in our series, we did not observe a prognostic value for HMGA1. This somewhat intriguing result can only be explained by our observation that chemotherapy modifies the course of the disease for patients having high expression of HMGA1 in the tumor, increasing the OS of these cases. In fact, when we considered only the patients treated with chemotherapy, we observed that HMGA1 expression lowers the risk of death to one half, independently from relevant clinicopathological factors.
5. Conclusions

Additional studies are needed, but our observation that GC patients with high levels of HMGA1 expression in the tumor benefit more from being treated with chemotherapy, should advise the selection of these patients for treatment, with expected improvements of their overall survival.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/curroncol29010005/s1, Figure S1: Kaplan-Meier curves showing the probability of DFS according to treatment options, Table S1: Chemotherapy regimens used in the 121 treated GC patients, namely in cases having either high or low expression of HMGA1.

Author Contributions: Conceptualization, D.P., R.A. and P.M.; methodology, D.P., D.F.P., P.F. and P.M.; software, R.A. and P.M.; validation, D.P., R.A. and P.M.; formal analysis, D.P., R.A. and P.M.; investigation, D.P., D.F.P., P.F., C.F.P., R.A. and P.M.; resources, R.A.; data curation, R.A. and P.M.; writing—original draft preparation, D.P., R.A. and P.M.; writing—review and editing, D.P., D.F.P., P.F., C.F.P., R.A. and P.M.; visualization, D.P., R.A. and P.M.; supervision, C.F.P., R.A. and P.M.; project administration, D.P., R.A. and P.M.; funding acquisition, C.F.P. and R.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by FEDER—Funduo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020 and by Portuguese funds through FCT—Fundacuo para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274); Project POCI-01-0145-FEDER-029017 funded by FCT and project Norte-01-0145-FEDER-000051—“Cancer Research on Therapy Resistance: From Basic Mechanisms to Novel Targets”, supported by North Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (FEDER). Diana Pádua acknowledges FCT for financial support through a PhD fellowship (SFRH/BD/146186/2019), co-sponsored by FSE (Funduo Social Europeu) through NORTE2020.

Institutional Review Board Statement: The study was approved by the ethics committee of CHSJ (Ethics Committee references CES 122/15 and CES 117/18).

Informed Consent Statement: Informed consent was obtained from all patients.

Data Availability Statement: The datasets used and/or analyzed during the current study are available from the corresponding authors on reasonable request.

Acknowledgments: The authors wish to acknowledge the tumor and tissue bank at Centro Hospitalar de Sáo João (CHSJ), Porto, Portugal for providing all the means to collect the human tissue samples included in this study.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References
1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef] [PubMed]
2. Laurén, P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol. Microbiol. Scand. 1965, 64, 31–49. [CrossRef] [PubMed]
3. Laurén, P. Histogenesis of intestinal and diffuse types of gastric carcinoma. Scand. J. Gastroenterol. Suppl. 1991, 180, 160–164. [PubMed]
4. Smyth, E.C.; Verbeij, M.; Allum, W.; Cunningham, D.; Cervantes, A.; Arnold, D.; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2016, 27, v38–v49. [CrossRef] [PubMed]
5. Song, Z.; Wu, Y.; Yang, J.; Yang, D.; Fang, X. Progress in the treatment of advanced gastric cancer. Tumor Biol. 2017, 39, 1010428317714626. [CrossRef]
6. Correa, P.; Piazuelo, M.B.; Camargo, M.C. The future of gastric cancer prevention. Gastric Cancer 2004, 7, 9–16. [CrossRef]
7. Digestive Cancers Europe (DiCE). Available online: https://digestivecancers.eu/gastric-cancer-map/ (accessed on 16 November 2021).

8. Gao, J.-P.; Xu, W.; Liu, W.-T.; Yan, M.; Zhu, Z.-G. Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell. World J. Gastroenterol. 2018, 24, 2567–2581. [CrossRef]

9. Gullo, I.; Carneiro, F.; Oliveira, C.; Almeida, G.M. Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications. Pathobiology 2018, 85, 50–63. [CrossRef]

10. Zou, J.; Wang, E. Cancer Biomarker Discovery for Precision Medicine: New Progress. Curr. Med. Chem. 2019, 26, 7655–7671. [CrossRef]

11. Pádua, D.; Figueira, P.; Ribeiro, I.; Almeida, R.; Mesquita, P. The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication. Front. Cell Dev. Biol. 2020, 8, 442. [CrossRef]

12. Bushweller, J.H. Targeting transcription factors in cancer—From undruggable to reality. Nat. Rev. Cancer 2019, 19, 611–624. [CrossRef] [PubMed]

13. Islam, Z.; Ali, A.M.; Naik, A.; Eldaw, M.; Decock, J.; Kolatkar, P.R. Transcription Factors: The Fulcrum Between Cell Development and Carcinogenesis. Front. Oncol. 2021, 11, 681377. [CrossRef]

14. Ozturk, N.; Singh, I.; Mehta, A.; Braun, T.; Barreto, G. HMGA proteins as modulators of chromatin structure during transcriptional activation. Front. Cell Dev. Biol. 2014, 2, 5. [CrossRef] [PubMed]

15. Colombo, D.F.; Burger, L.; Baubec, T.; Schübeler, D. Binding of high mobility group A proteins to the mammalian genome occurs as a function of AT-content. PLoS Genet. 2017, 13, e1007102. [CrossRef] [PubMed]

16. Wei, F.; Zhang, T.; Deng, S.-C.; Wei, J.-C.; Yang, P.; Wang, Q.; Chen, Z.-P.; Li, W.-L.; Chen, H.-C.; Hu, H.; et al. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways. Cancer Lett. 2019, 450, 1–13. [CrossRef]

17. Cao, X.P.; Cao, Y.; Zhao, H.; Yin, J.; Hou, P. HMGA1 promoting gastric cancer oncogenic and glycolytic phenotypes by regulating c-myc expression. Biochem. Biophys. Res. Commun. 2019, 516, 457–465. [CrossRef]

18. Akaboshi, S.-I.; Watanabe, S.; Hino, Y.; Sekita, Y.; Xi, Y.; Araki, K.; Yamamura, K.-I.; Oshima, M.; Ito, T.; Baba, H.; et al. HMGA1 Is Induced by Wnt/β-Catenin Pathway and Maintains Cell Proliferation in Gastric Cancer. Am. J. Pathol. 2009, 175, 1675–1685. [CrossRef]

19. Parisi, S.; Piscitelli, S.; Passaro, F.; Russo, T. HMGA Proteins in Stemness and Differentiation of Embryonic and Adult Stem Cells. Int. J. Mol. Sci. 2020, 21, 362. [CrossRef]

20. Shah, S.N.; Kerr, C.; Cope, L.; Zambidis, E.; Liu, C.; Hillion, J.; Belton, A.; Huso, D.L.; Resar, L.M.S. HMGA1 Reprograms Somatic Cells into Pluripotent Stem Cells by Inducing Stem Cell Transcriptional Networks. PLoS ONE 2012, 7, e48533. [CrossRef] [PubMed]

21. Ben-Porath, I.; Thomson, M.W.; Carey, V.J.; Ge, R.; Bell, G.W.; Regev, A.; Weinberg, R.A. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 2008, 40, 499–507. [CrossRef]

22. Fusco, A.; Fedele, M. Roles of HMGA proteins in cancer. Nat. Rev. Cancer 2007, 7, 899–910. [CrossRef] [PubMed]

23. Wang, Y.; Hu, L.; Zheng, Y.; Guo, L. HMGA1 in cancer: Cancer classification by location. J. Cell. Mol. Med. 2019, 23, 2293–2302. [CrossRef] [PubMed]

24. Shah, S.N.; Cope, L.; Poh, W.; Belton, A.; Roy, S.; Talbot, C.C., Jr.; Sukumar, S.; Huso, D.L.; Resar, L.M. HMGA1: A Master Regulator of Tumor Progression in Triple-Negative Breast Cancer Cells. PLoS ONE 2013, 8, e63419. [CrossRef] [PubMed]

25. Sumter, T.F.; Xian, L.; Huso, T.; Koo, M.; Chang, Y.T.; Almasri, T.N.; Chia, L.; Inglis, C.; Reid, D.; Resar, L.M.S. The High Mobility Group A1 (HMGA1) Transcripome in Cancer and Development. Curr. Mol. Med. 2016, 16, 353–393. [CrossRef] [PubMed]

26. Shah, S.N.; Resar, L.M. High mobility group A1 and cancer: Potential biomarker and therapeutic target. Histol. Histopathol. 2012, 27, 567–579.

27. Jin, G.-H.; Shi, Y.; Tian, Y.; Cao, T.-T.; Mao, Y.; Tang, T.-Y. HMGA1 accelerates the malignant progression of gastric cancer through stimulating EMT. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 3642–3647.

28. Yang, Q.; Wang, Y.; Li, M.; Wang, Z.; Zhang, J.; Dai, W.; Pei, M.; Hong, L.; Xiao, Y.; Hu, H.; et al. HMGA1 promotes gastric cancer growth and metastasis by transactivating SUZ12 and CCDC43 expression. Aging 2021, 13, 16043–16061. [CrossRef]

29. Huang, R.; Hu, D.; Dai, W.; Yang, F. Overexpression of HMGA1 correlates with the malignant status and prognosis of breast cancer. Mol. Cell. Biochem. 2015, 404, 251–257. [CrossRef]

30. Nam, E.S.; Kim, D.H.; Cho, S.J.; Chae, S.W.; Kim, H.Y.; Kim, S.M.; Han, J.J.; Shin, H.S.; Park, Y.E. Expression of HMG1(Y) associated with malignant phenotype of human gastric tissue. Histopathology 2003, 42, 466–471. [CrossRef]

31. Resar, L.M.S. The High Mobility Group A1 Gene: Transforming Inflammatory Signals into Cancer? Cancer Res. 2010, 70, 436–439. [CrossRef]

32. Chiappetta, G.; Botti, G.; Monaco, M.; Pasquinelli, R.; Pentimalli, F.; Di Bonito, M.; D’Aiuto, G.; Fedele, M.; Juliano, R.; Palmieri, E.A.; et al. HMGA1 Protein Overexpression in Human Breast Carcinomas: Correlation with ErbB2 expression. Clin. Cancer Res. 2004, 10, 7637–7644. [CrossRef]

33. Masciullo, V.; Baldassarre, G.; Pentimalli, F.; Berlingieri, M.T.; Boccia, A.; Chiappetta, G.; Palazzo, J.; Manfioletti, G.; Giancotti, V.; Viglietto, G.; et al. HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis 2003, 24, 1191–1198. [CrossRef]

34. Fu, F.; Wang, T.; Wu, Z.; Feng, Y.; Wang, W.; Zhou, S.; Ma, X.; Wang, S. HMGA1 exacerbates tumor growth through regulating the cell cycle and accelerates migration/invasion via targeting miR-221/222 in cervical cancer. Cell Death Dis. 2018, 9, 594. [CrossRef]
35. Sgarra, R.; Pegoraro, S.; Ros, G.; Penzo, C.; Chieffiari, E.; Foti, D.; Brunetti, A.; Manfioletti, G. High Mobility Group A (HMGA) proteins: Molecular instigators of breast cancer onset and progression. *Biochim. Biophys. Acta Rev. Cancer* **2018**, *1869*, 216–229. [CrossRef]

36. Liang, L.; Li, X.; Zhang, X.; Lv, Z.; He, G.; Zhao, W.; Ren, X.; Li, Y.; Bian, X.; Liao, W.; et al. MicroRNA-137, an HMGA1 Target, Suppresses Colorectal Cancer Cell Invasion and Metastasis in Mice by Directly Targeting FMNL2. *Gastroenterology* **2013**, *144*, 624–635.e4. [CrossRef]

37. Zhong, J.; Liu, C.; Chen, Y.-J.; Zhang, Q.-H.; Yang, J.; Kang, X.; Chen, S.-R.; Wen, G.-B.; Zu, X.-Y.; Cao, R.-X. The association between S100A13 and HMGA1 in the modulation of thyroid cancer proliferation and invasion. *J. Transl. Med.* **2016**, *14*, 80. [CrossRef] [PubMed]

38. Sun, B.; Zhang, Y.; Zhou, L.; Yin, L.; Li, F.; Li, C.; Xia, J. The proliferation of cervical cancer is promoted by miRNA-125b through the regulation of the HMGA1. *Oncotargets Ther.* **2019**, *12*, 2767–2776. [CrossRef]

39. Chen, Y.N.; Ren, C.C.; Yang, L.; Nai, M.M.; Xu, Y.M.; Zhang, F.; Liu, Y. MicroRNA let-7d-5p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1. *Int. J. Oncol.* **2019**, *54*, 1771–1784. [CrossRef] [PubMed]

40. Zhang, Z.; Wang, H. HCP5 Promotes Proliferation and Contributes to Cisplatin Resistance in Gastric Cancer Through miR-519d/HMGA1 Axis. *Cancer Manag. Res.* **2021**, *13*, 787–794. [CrossRef]

41. Wang, C.-Q. MiR-195 reverses 5-FU resistance through targeting HMGA1 in gastric cancer cells. *Eur. Rev. Med. Pharmacol. Sci.* **2019**, *23*, 3771–3778. [PubMed]

42. Mesquita, P.; Freire, A.F.; Lopes, N.; Gomes, R.; Azevedo, D.; Barros, R.; Pereira, B.; Cavadas, B.; Pópulo, H.; Boaventura, P.; et al. Expression and Clinical Relevance of SOX9 in Gastric Cancer. *Dis. Markers* **2019**, *2019*, 8267021. [CrossRef] [PubMed]

43. Jun, K.-H.; Jung, J.-H.; Choi, H.-J.; Shin, E.-Y.; Chin, H.-M. HMGA1/HMGA2 protein expression and prognostic implications in gastric cancer. *Int. J. Surg.* **2015**, *24*, 39–44. [CrossRef] [PubMed]

44. D’Angelo, D.; Mussnich, P.; Rosa, R.; Blanco, R.; Tortora, G.; Fusco, A. High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. *BMC Cancer* **2014**, *14*, 851. [CrossRef] [PubMed]

45. Loria, R.; Laquintana, V.; Bon, G.; Trisciuoglio, D.; Frapolli, R.; Covello, R.; Amoreo, C.A.; Ferraresi, V.; Zoccali, C.; Novello, M.; et al. HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance. *Oncogene* **2018**, *37*, 5926–5938. [CrossRef] [PubMed]

46. D’Angelo, D.; Mussnich, P.; Arra, C.; Battista, S.; Fusco, A. Critical role of HMGA proteins in cancer cell chemoresistance. *J. Mol. Med.* **2017**, *95*, 353–360. [CrossRef]

47. Dalerba, P.; Sahoo, D.; Paik, S.; Guo, X.; Yothers, G.; Song, N.; Wilcox-Fogel, N.; Forgó, E.; Rajendran, P.S.; Miranda, S.P.; et al. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. *N. Engl. J. Med.* **2016**, *374*, 211–222. [CrossRef]

48. Lee, H.; Lee, H.H.; Lim, C.Y.; Lee, J. The utility of high-mobility group A2 overexpression for predicting the prognosis of gastric cancer patients and its contribution to poor prognosis via chemoresistance and the propensity for the occurrence of carcinomatosis peritonei. *Surgery* **2021**, *169*, 1213–1220. [CrossRef]